

Review

The many faces of estrogen signaling

Peter Vrtačnik, Barbara Ostanek, Simona Mencej-Bedrač, Janja Marc*

University of Ljubljana, Faculty of Pharmacy, Department of Clinical Biochemistry, Ljubljana, Slovenia

*Corresponding author: janja.marc@ffa.uni-lj.si

Abstract

Estrogens have long been known as important regulators of the female reproductive functions; however, our understanding of the role estrogens play in the human body has changed significantly over the past years. It is now commonly accepted that estrogens and androgens have important functions in both female and male physiology and pathology. This is in part due to the local synthesis and action of estrogens that broadens the role of estrogen signaling beyond that of the endocrine system. Furthermore, there are several different mechanisms through which the three estrogen receptors (ERs), ER α , ER β and G protein-coupled estrogen receptor 1 (GPER1) are able to regulate target gene transcription. ER α and ER β are mostly associated with the direct and indirect genomic signaling pathways that result in target gene expression. Membrane-bound GPER1 is on the other hand responsible for the rapid non-genomic actions of estrogens that activate various protein-kinase cascades. Estrogen signaling is also tightly connected with another important regulatory entity, i.e. epigenetic mechanisms. Posttranslational histone modifications, microRNAs (miRNAs) and DNA methylation have been shown to influence gene expression of ERs as well as being regulated by estrogen signaling. Moreover, several coregulators of estrogen signaling also exhibit chromatin-modifying activities further underlining the importance of epigenetic mechanisms in estrogen signaling. This review wishes to highlight the newer aspects of estrogen signaling that exceed its classical endocrine regulatory role, especially emphasizing its tight intertwinement with epigenetic mechanisms.

Key words: estrogen signaling; extragonadal synthesis; epigenetic mechanisms; miRNA; DNA methylation

Received: April 22, 2014

Accepted: August 14, 2014

Introduction

Estrogens are perceived mainly as ovarian sex hormones responsible for cellular proliferation and growth of tissues related to reproduction. In premenopausal women ovaries represent by far the most important source of circulating estrogens, although during pregnancy, placenta also secretes significant amounts of estrogens into the circulation (1). In addition to the effects on the female reproductive functions, estrogens also play a significant role in the regulation of skeletal homeostasis, lipid and carbohydrate metabolism, electrolyte balance, skin physiology, the cardiovascular system and the central nervous system (1,2). Due to this wide regulatory role, it is not surprising that estrogens also have an important function in male physiology and cannot be viewed solely as female

sex hormones. Postmenopausal women, due to the decline in their ovary function, and men are largely dependent on local synthesis of estrogens in extragonadal target tissues. This local production of estrogens extends their signaling from endocrine to paracrine, autocrine and intracrine (3). The complexity is further increased by multiple mechanisms of estrogen signaling, namely the well established direct and indirect genomic signaling, the fast non-genomic actions of steroid hormones and ligand-independent signaling (4). Moreover, estrogen signaling is also tightly intertwined with epigenetic mechanisms which have been an important focus of research in recent years. Posttranslational histone modifications, microRNAs (miRNAs) and DNA methylation are im-

portant regulators of gene expression acting both upstream and downstream from estrogen receptors (ERs). Certain coregulators of estrogen signaling are able to induce posttranslational changes to histone proteins and specific epigenetic changes are necessary for initiation of transcription. Furthermore, different pathologies, aging and environmental factors can potentially influence estrogen signaling and regulation through induction of epigenetic changes (5,6). This review wishes to highlight additional aspects of estrogen signaling that exceed the classical concept of endocrine regulation and particularly point out the close relationship between estrogen signaling and epigenetic mechanisms.

Distribution of estrogen synthesis in the human organism

In addition to ovaries, several extragonadal tissues also produce estrogens. These include mesenchymal cells of the adipose tissue including that of the breast, osteoblasts and chondrocytes, aortic smooth muscle cells and vascular endothelium, as well as numerous parts of the brain (7). In contrast to the importance of ovaries in premenopausal women, in postmenopausal women and men extragonadal tissues represent both the predominant source of estrogen synthesis and the main site of estrogen action. Only estrogens that escape local metabolism can enter the circulation, sug-

gesting that plasma levels of estrogens reflect rather than direct estrogen action in postmenopausal women and men (7). This was confirmed by several studies comparing tissue and plasma sex steroid concentrations. They showed that in postmenopausal women concentrations of estrogens in breast cancer and abdominal adipose tissue were several fold higher than in plasma (8-10). As a consequence, the levels of active steroid hormones in the circulation of postmenopausal women and men are probably of no significance in assessing their concentrations in individual extragonadal tissues (7). Sex- and menopause-based differences in estrogen synthesis are summarized in Table 1.

In contrast to ovaries, estrogen production in extragonadal tissues is dependent on the availability of C₁₉ steroid precursors, namely testosterone, androstenedione, dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEAS). In target tissues, testosterone can be converted to either 5 α -dihydrotestosterone (DHT), the principal ligand for androgen receptors, or to 17 β -estradiol, the most potent of the estrogens. Similarly, although requiring several enzymatic reactions, DHEAS, DHEA and androstenedione can also be converted to 17 β -estradiol or DHT (Figure 1). Distribution of the required enzymes varies in different extragonadal tissues, making the metabolism of DHEAS and DHEA tissue-specific. In plasma of postmenopausal women and men, DHEAS is by far the most abundant steroid precursor, followed by

TABLE 1. Summary of sex- and menopause-based differences in estrogen synthesis (1,4,7,11,76).

	Premenopausal women	Postmenopausal women	Men
Sources of circulating 17 β -estradiol	ovaries (around 95%), adrenal cortex (around 5%)	extragonadal tissues (close to 100%)	extragonadal tissues (close to 80%), testes (around 20%)
Plasma levels of 17 β -estradiol	0.11-2.20 nM (depending on the phase of the cycle)	around 0.04 nM	around 0.10 nM
Intracrine formation of 17 β -estradiol in extragonadal tissues	estimated at around 75%	estimated at around 100%	estimated at around 100%
Source molecules for 17 β -estradiol synthesis	blood-derived cholesterol and acetyl coenzyme A	testosterone, androstenedione, DHEA and DHEAS	testosterone, androstenedione, DHEA and DHEAS

DHEA – dehydroepiandrosterone; DHEAS – dehydroepiandrosterone sulphate.




FIGURE 1. Schematic representation of estrogen synthesis in extragonadal tissues.

Estrogens and androgens are produced from C_{19} steroid precursors through several enzymatic conversions. Testosterone can be converted to the most active ligand on the androgen receptor, i.e. DHT, or the most active ligand on the estrogen receptor, i.e. 17β -estradiol, in a single reaction.

3β -HSD – 3β -hydroxysteroid dehydrogenase; 17β -HSD – 17β -hydroxysteroid dehydrogenase; DHEA – dehydroepiandrosterone; DHEAS – dehydroepiandrosterone sulfate; DHT – 5α -dihydrotestosterone.

DHEA. Concentrations of both are several orders of magnitude greater than those of the active sex steroids, although their secretion and plasma concentrations decline significantly with advancing age. Interestingly, in postmenopausal women even the concentration of circulating testosterone exceeds that of 17β -estradiol by an order of magnitude. Approximately 25% of this testosterone is secreted directly from the ovaries, while the rest is formed in extragonadal tissues from steroid precursors. Androstenedione and DHEA are derived from both the adrenal cortex and the ovaries, whereas DHEAS is secreted entirely from the adrenals. The sheer amount of DHEAS and DHEA present in the circulation means they form a large

reservoir of precursors available for the conversion to testosterone and estrogens in extragonadal tissues. Since testosterone can be converted in one reaction to either a ligand active at androgen receptor or a ligand active at estrogen receptors, it can be viewed as a circulating pro-hormone. Similar to the importance of estrogens in male physiology, high circulating concentrations of androgens indicate their significant role in women as well. In this light, it is impossible to separate estrogen signaling from androgen signaling or give them gender-specific roles. Therefore, it is always important to consider both regulatory pathways and their tight intertwinement in either women or men (3,7,11). This fact only further accentuates the central role of extragonadal production of steroid hormones, for a long time an overlooked aspect of estrogen signaling.

Structure and function of estrogen receptors

Estrogens exert their effects by binding to their designated receptors. In spite of the importance of estrogen signaling there are only three known receptors that mediate all of the estrogens' effects. $ER\alpha$ was discovered first and is the most thoroughly investigated. Significantly homologous $ER\beta$ was identified almost four decades later and showed to have distinct, non-redundant roles (12). Another decade had to pass for the association of G protein-coupled estrogen receptor 1 (GPER1) with estrogen signaling. Characteristics of all three receptors are summarized in Table 2.

$ER\alpha$ has at least three and $ER\beta$ at least five different isoforms. Unlike the full length $ER\alpha$, the two shorter $ER\alpha$ isoforms lack the N-terminal domain. Since they have the ability to heterodimerize with the full length $ER\alpha$, they are able to repress $ER\alpha$ activity. The shortest $ER\alpha$ isoform termed $ER\alpha 36$, also acts as a membrane located ER able to interact with GPER1. The four shorter $ER\beta$ isoforms differ from the full length $ER\beta$ mostly in their ligand-binding domain, resulting in compromised ligand-binding ability. $ER\beta$ isoforms that are unable to bind ligands or coactivators and have no transcriptional activity dimerize preferentially with $ER\alpha$,

TABLE 2. Characteristics of estrogen receptors (2,12-15,17,18,77).

Receptor characteristic	ER α	ER β	GPER1
Receptor superfamily	nuclear steroid hormone receptor superfamily		G-protein coupled receptor superfamily
Type	nuclear		membrane-bound G protein-coupled
Structure	DNA-binding domain, ligand-binding domain, N-terminal domain		7 transmembrane α -helical regions, 4 extracellular and 4 cytosolic segments
Chromosome region	6q25.1	14q23.2	7p22.3
Number of isoforms	3	5	1
Size	595 aa	530 aa	375 aa
Distribution in human tissues	uterus, epididymis, breast, liver, kidney, white adipose tissue, prostate, ovary, testes, skeleton, brain	colon, salivary gland, vascular endothelium, lung, bladder, prostate, ovary, testes, skeleton, brain	central and peripheral nervous system, uterus, ovaries, mammary glands, testes, spermatogonial cells, gastrointestinal system, pancreas, kidney, liver, adrenal and pituitary glands, bone tissue, cardiovascular system, immune cells
Tamoxifen activity	partial agonist	antagonist	agonist

ER – estrogen receptor; GPER1 – G protein-coupled estrogen receptor 1; aa – amino acids.

thereby silencing ER α signaling. This indicates that different ER α and ER β isoforms can have a very diverse influence on estrogen signaling and target gene regulation (13,14). Furthermore, relative concentrations of ER α and ER β in a given cell significantly influence its response to various ligands. Homodimers of ER α and ER β were shown to regulate largely different sets of genes from that of ER α / β heterodimers. This is supported by the observation of completely distinct cellular responses by ER subtype-specific and non-specific agonists. It was also suggested that ER β exerts an inhibitory effect on ER α -mediated signaling. Slightly different, in some instances even opposite, roles of ER α and ER β are additionally underscored by differences in their expression in various tissues and organs (2).

GPER1, a plasma membrane receptor formerly known as an orphan G protein-coupled receptor 30 (GPR30), is genetically and structurally unrelated to ER α and ER β . It is located on the cell surface and is responsible for rapid estrogen signaling, although certain ER α and ER β variants have also been associated with the plasma membrane and the non-genomic signaling (13,14). GPER1 functions and is expressed independently from the two ERs. It has high affinity, limited capacity, displaceable, single binding sites for estrogens. In

comparison to nuclear ERs, its binding affinity for 17 β -estradiol is considerably lower and the rates of association and dissociation are very rapid and completed within a few minutes. It displays largely similar ligand binding specificities to those of the nuclear ERs with certain distinct differences. The specificity of GPER1 for estrogens is also underlined by the fact, that other steroid hormones possess very low binding affinities for this receptor (15-17).

Mechanisms of estrogen signaling

Estrogen dependent signaling can be roughly divided into genomic and non-genomic, based on the outcome of cellular events, e.g. modulation of gene expression or activation of signaling cascades, respectively. Furthermore, binding of the estrogen-ER complex to DNA can be either direct or indirect. Different mechanisms of estrogen signaling are represented in Figure 2.

Direct genomic signaling

Direct genomic signaling pathway is considered as the classical mechanism of estrogen signaling. The binding of 17 β -estradiol to ER α or ER β in the cytoplasm of target cells causes conformational chang-




FIGURE 2. The representation of different mechanisms of estrogen signaling.

(I.) Direct genomic signaling pathway, considered the classical mechanism of estrogen signaling, promotes target gene expression by binding the E2-ER complex directly to the ERE. (II.) In the case of indirect genomic signaling pathway, E2-activated ERs bind DNA through protein-protein interactions with other classes of transcription factors at their respective response elements. (III.) Non-genomic signaling pathway starts with the binding of E2 to the ERs located at the plasma membrane resulting in the activation of various protein-kinase cascades. These can eventually lead to changes in gene expression due to phosphorylation of transcription factors. (IV.) Ligand-independent signaling pathway causes ER activation and target gene transcription through phosphorylation of ERs or their associated coregulators.

E2 – 17β-estradiol; ER – estrogen receptor; ERE – estrogen response element; P – phosphate group; TF – transcription factor; TF RE – transcription factor response element.

es that enable receptor dimerization, translocation to the nucleus and binding to the estrogen response elements (EREs) located in or near the promoters of target genes. Binding of the ligand to the receptor also triggers recruitment of a variety of coregulators in a complex that alters chromatin structure and facilitates recruitment of the RNA polymerase II transcriptional machinery. In this way, estrogen-ER complex acts as a transcriptional activator promoting gene expression (18).

Indirect genomic signaling

17β-estradiol can also influence expression of genes that do not harbour EREs in their promoter regions. In fact, around one third of the estrogen responsive genes lack ERE-like sequences. In the case of ERE-independent genomic signaling ligand-activated ERs do not bind DNA directly, but rather through protein-protein interactions with other classes of transcription factors at their respective response elements. This mode of action enables activation or repression of target gene expression and significantly broadens estrogens' regulatory influence. One of the best described examples includes interaction of estrogen-ER complex with FBJ murine osteosarcoma viral oncogene homolog (FOS) and jun proto-oncogene (JUN) proteins at the activator protein 1 (AP-1) binding sites in genes encoding ovalbumin, insulin-like growth factor 1 (*IGF1*), collagenase, cyclin D1 (*CCND1*) and choline acetyltransferase. The result depends on the ER subtype and type of the ligand. Other transcription factors that facilitate estrogen signaling also include Sp1 transcription factor, nuclear factor κB (NFκB), CCAAT/enhancer binding protein β (C/EBPβ), GATA binding protein 1 (GATA1) and signal transducer and activator of transcription 5 (STAT5) (19).

Non-genomic signaling

It has been known for a long time that certain estrogen-induced changes are simply too rapid to be associated with target gene transcription and subsequent protein synthesis. Non-genomic actions are common to steroid hormones and are usually associated with the activation of various protein-kinase cascades that can eventually lead to indirect changes in gene expression due to phosphorylation of transcription factors. Non-genomic estrogen signaling is most often associated with a subset of membrane bound ER, e.g. GPER1 and certain variants of ERα and ERβ. Binding of estrogens to ERs located at the cell surface can cause mobilization of intracellular calcium, stimulation of adenylate cyclase activity and cyclic adenosine monophosphate (cAMP) production, activation of the mitogen-activated protein kinase (MAPK) sign-

aling pathway, activation of the phosphoinositol 3-kinase signaling pathway and activation of membrane tyrosine kinase receptors (14,19). GPER1 is specifically associated with the stimulation of adenylyl cyclase and activation of EGFR (15). Molecular mechanisms underlying non-genomic estrogen signaling are without a doubt diverse and numerous and may depend on a number of conditions, like the availability of signal transduction molecules and downstream targets, suggesting a cell type-specific mechanism.

Ligand-independent signaling

In addition to genomic and non-genomic ligand-dependent estrogen signaling, ERs can also be activated in the absence of 17 β -estradiol or another suitable ligand. Phosphorylation of the receptors on certain residues or their associated coregulators can cause ligand-independent ER activation. The two most often targeted amino acids are serine and tyrosine. Signaling pathways responsible for this modulation include regulators of general cellular phosphorylation state, such as protein kinase A (PKA) or protein kinase C (PKC), extracellular signals such as peptide growth factors, cytokines or neurotransmitters and cell cycle regulators. Peptide growth factors represent especially important group of estrogen-independent ER activators that include epidermal growth factor (EGF), insulin, IGF1 and transforming growth factor β (TGF β). Principle intermediates between growth factors and ERs are the guanine nucleotide-binding protein p21^{ras} and MAPK phosphorylation cascades, among others. Additional extracellular signals that modulate ER activity include heregulin, interleukin 2 and dopamine, as well as regulatory proteins cyclin A and D1 (12).

It has become clear that the classic genomic mechanism contributes only a small part to the complexity of estrogen signaling. It is expected that 17 β -estradiol is able to regulate expression of the same target gene through multiple mechanisms, both genomic and non-genomic. In addition, the same promoter sequence can harbour both ERE as well as response elements associated with other transcription factors. The final gene response therefore depends on multiple factors including

combination of transcription factors present on the gene promoter, expression levels and cellular localization of all three ERs, their numerous coregulators, and signaling components, as well as the nature of the stimuli. Since these variables can differ significantly among various cell types, it is possible that estrogens use distinct signaling pathways depending on the cellular context and in this way ensure very precise and cell-specific regulation of target gene expression.

Interactions of epigenetic mechanisms and estrogen signaling

Estrogen signaling controls several physiological processes by directly and indirectly regulating target gene transcription. Another group of important gene expression regulators receiving a lot of attention in recent years consists of epigenetic mechanisms. These include posttranslational histone modifications, miRNA and DNA methylation and are characterized by their ability to influence gene expression without altering the DNA sequence in a stable and potentially heritable manner.

Epigenetic mechanisms

Perhaps the most complex of the three, histone proteins can be subjected to various posttranslational modifications including acetylation, methylation, phosphorylation, ubiquitination, deimination and sumoylation. They are usually restricted to lysine and arginine residues but can also occur on serine and threonine. High levels of acetylation and trimethylated lysine (K) residue 4 of histone H3 (H3K4), H3K36 and H3K79 are associated with a more relaxed actively transcribed conformation of chromatin called euchromatin. Low levels of acetylation and high levels of H3K9, H3K27 and H4K20 methylation on the other hand result in a more condensed transcriptionally inactive heterochromatin. Most posttranslational histone modifications are dynamic and are regulated by families of enzymes that either bind or remove specific functional groups. For example, histone acetyltransferases (HATs) add, while histone deacetylases (HDACs) remove acetylation marks. Histone methyltransferases add methyl groups to arginine and

lysine residues, while deiminases and lysine demethylases reverse these changes. There is also a similar relationship between histone kinases and phosphatases (20,21).

miRNAs perform their regulatory role in a very different way. They are small, approximately 21 nucleotide-long, non-coding RNAs usually associated with target gene repression. They facilitate binding of the RNA-induced silencing complex (RISC) to the target mRNA, usually within its 3' UTR region. When miRNA sequence completely matches that of the target, mRNA is degraded. More often, miRNAs bind imperfectly to their targets, resulting in translational inhibition without mRNA cleavage. This can result in decreased target protein levels without any changes in the mRNA concentration. Individual miRNAs generally regulate multiple target genes at modest levels and many different miRNAs can target the same transcript (22).

Similar to miRNA-mediated posttranscriptional regulation, DNA methylation is mainly associated with gene repression. It is a reversible covalent binding of a single methyl group to the 5' carbon of a cytosine residue located next to a guanosine. These dinucleotides commonly annotated as CpGs, occur with higher than expected frequency in regions referred to as CpG islands. These are unevenly distributed throughout the genome, located in promoter regions of genes, within genes and in intergenic locations. DNA methylation patterns are established by three DNA methyltransferases (DNMTs), namely DNMT1, DNMT3A and DNMT3B, and can be preserved during DNA replication and mitosis. This enables the inheritance of DNA methylation-mediated repression of target gene expression. The mechanisms of DNA demethylation which can be either passive or active are not yet fully elucidated (20).

Coregulators of estrogen signaling

As already mentioned, recruitment of a variety of coregulators in large multifunctional protein complexes is intrinsic to estrogen signaling. Most of these coregulators interact with many members of the nuclear receptor superfamily and are involved in chromatin remodeling, histone modifications,

transcription initiation and elongation, splicing and proteasomal degradation. In addition to gene activation through coactivator recruitment, estrogen signaling is also associated with repression of transcription assisted by corepressors (12,13). Coactivators associated with estrogen-mediated transcription include v-src avian sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (SRC1), nuclear receptor coactivator 2 (NCOA2), NCOA3, proline, glutamate and leucine rich protein 1 (PELP1), CREB binding protein (CBP), E1A binding protein p300 (p300), K(lysine) acetyltransferase 2B (PCAF/KAT2B), coactivator-associated arginine methyltransferase 1 (CARM1) and protein arginine methyltransferase 1 (PRMT1) while estrogen-induced repression recruits corepressors nuclear receptor corepressor 1 (NCOR1), NCOR2 and metastasis associated 1 (MTA1) among others (23). Even though coregulators are involved in a multitude of transcriptional steps we would like to point out their role as intermediates between transcriptional coregulation and epigenetic changes. A number of coregulators possess chromatin-modifying activities such as acetyltransferase and methyltransferase activity. In fact, histone acetylation is a necessary early step in transcription initiation marking active chromatin sites. Acetylation, as well as certain methylation marks attract additional transcriptional coactivators which in turn recruit general transcriptional machinery, including RNA polymerase and its accessory factors. The most commonly utilized HATs include p300, CBP, PCAF, KAT2A and KAT5. Conversely, removal of these acetylation marks from histones by corepressor complexes is associated with target gene silencing. Common HDACs include sirtuin 1 (SIRT1) and HDAC1-4 (24). Clearly chromatin modifications are integral to estrogen-mediated transcriptional regulation and gene expression in general.

Epigenetic regulation of estrogen signaling

Another contact point between estrogen signaling and epigenetic mechanisms is the epigenetic control of ER gene expression. Through the regulation of ER levels the epigenetic control extends to all ER target genes and estrogen-regulated processes. Several studies have shown that his-

tone-modifying enzymes like, e.g. histone deacetylases HDAC1 and HDAC3 and histone methyltransferase suppressor of variegation 3-9 homolog 1 (*Drosophila*) (SUV39H1), are at least in part responsible for the reduction of *ERα* expression in oncological settings, specifically in breast cancer (25-29). Conversely, histone deacetylase SIRT1 activity is necessary for *ERα* expression in breast cancer. However, it was shown that SIRT1 is not directly associated with the *ERα* promoter and does not participate in histone modifications but is rather involved in the formation of basal transcription factor complexes at the *ERα* promoter. In addition, *ERα* and SIRT1 proteins directly interact to form transcriptional activator or repressor complexes depending on the targeted gene. This indicates that SIRT1 has other regulatory roles in addition to histone deacetylation (29,30). The balance between HATs and HDACs present at *ERα* gene promoter was also pointed out as an important determinant of gene expression and repression. Furthermore, it was suggested that histone-modifying enzymes establish a more transient gene repression followed by the recruitment of DNMTs to the same regulatory complexes in order to methylate DNA for long-term gene silencing (26,31). Despite the lack of data on direct associations between different histone modifications and *ERβ* gene expression, several studies reported re-expression of *ERβ* after treatment with trichostatin A (TSA), an HDAC inhibitor, in breast, ovarian and prostate cancer cell lines. This effect was further increased when a DNMT inhibitor, 5-aza-2'-deoxycytidine (5-AZA), was added to the TSA treatment (32-35). This supports the observed complementary roles of histone deacetylation and DNA methylation in repressing gene expression. An increase in *ERβ* expression was also observed in a non-oncological setting after exposure to sodium butyrate, another HDAC inhibitor (36).

Similarly, miRNAs were also identified as important regulators of ER gene expression. *ERα* was shown to be directly targeted by numerous miRNAs, including miR-18a, miR-22, and miR-206 (for a more comprehensive list see Table 3) (37-45). There is markedly less information available about miRNAs targeting *ERβ* and *GPER1*. So far only miR-92 was

TABLE 3. Experimentally validated miRNAs that directly regulate ER gene expression.

miRNA	Target gene	References
miR-18a		
miR-18b		
miR-19a		
miR-19b		
miR-20b		
miR-22		
miR-130a		
miR-193b	<i>ERα</i>	(37-45)
miR-206		
miR-221		
miR-222		
miR-302c		
let-7a		
let-7b		
let-7i		
miR-92	<i>ERβ</i>	(46)

miRNA – microRNA; ER – estrogen receptor.

identified as a miRNA that directly targets *ERβ*, while no such miRNAs are known for *GPER1* (22, 46).

DNA methylation is probably the most thoroughly analyzed epigenetic mechanism responsible for ER silencing in numerous malignancies. As already indicated, expression of several *ERα* and *ERβ* isoforms was shown to be inversely correlated with the methylation of CpGs at their respective promoters. This association was observed repeatedly in multiple cell lines, primary cell cultures and tissue samples of hematopoietic neoplasms, endometrial, prostate, breast, and ovarian cancers, among others (47-53).

Even though the described studies focused mainly on epigenetic changes that resulted in ER silencing in numerous malignancies, they prove beyond a reasonable doubt that epigenetic mechanisms play an important role in the regulation of ER expression and consequently in the regulation of estrogen signaling.

Estrogen-mediated control of epigenetic mechanisms

The classic view of estrogen receptors as transcription factors suggests that the roles of estrogen sig-

naling and epigenetic regulation can also be reversed, meaning that estrogen signaling is also able to regulate expression of certain chromatin-modifying enzymes and miRNAs (54).

An *in vivo* study showed a stimulatory effect of estrogen replacement on SIRT1 protein levels in bone marrow of estrogen-deficient mice (55). Activation of *SIRT1* transcription by 17β-estradiol through ERα was also shown in breast cancer cell lines (29). Similarly, *HDAC6* expression is also positively regulated by estrogen signaling (56). Furthermore, a transcriptome profiling study in primary osteoblasts identified lysine (K)-specific methyltransferase 2D (*MLL2*) as an estrogen-responsive gene (57). These examples clearly show that estrogen signaling plays an important role in the regulation of certain histone-modifying enzymes.

17β-estradiol also significantly upregulates and downregulates expression of numerous miRNAs. All three ERs were shown to directly and indirectly influence transcription of miRNAs in tumorous and normal cells. ERα-mediated estrogen signaling inhibits transcription of miR-21, miR-26a, miR-140, miR-181b and miR-206, while it stimulates expression of miR-190a, miR-191, miR-203 and miR-425 among others (37,58-63). ERβ is on the other hand associated with downregulation of miR-17, miR-30a, miR-200a and miR-200b, and upregulation of miR-23b, miR-24-1 and miR-27b among others (64, 65). Additionally, binding of 17β-estradiol specifically to GPER1 was shown to repress the expression of miR-338-3p (66). A more comprehensive list of ER-regulated miRNAs is presented in Table 4.

As mentioned earlier, DNMTs are responsible for maintenance and *de novo* methylation of DNA. Estrogen signaling was clearly shown to influence the expression of DNMTs, although the results are quite diverse. *DNMT1* was shown to be either downregulated or unaffected by 17β-estradiol, *DNMT3A* was downregulated, upregulated or unaffected in the same conditions, while *DNMT3B* could be downregulated or upregulated. There are many potential explanations for this discordance, the most obvious being differences between various malignant and non-malignant cell lines used by researchers, differences in their ER levels and

TABLE 4. ER-mediated regulation of miRNA expression.

Type of ER-mediated regulation of miRNA expression	miRNA	References
ERα-mediated downregulation	let-7g miR-16 miR-21 miR-23a miR-26a miR-26b miR-27a miR-34b miR-107 miR-125a miR-140 miR-143	miR-145 miR-181b miR-181c miR-195 miR-203 miR-206 miR-221 miR-222 miR-515-5p miR-570 miR-618 (37,42,58, 59,78-85)
ERα-mediated upregulation	miR-19a miR-19b miR-20a miR-20b miR-25 miR-101 miR-135a miR-190a	miR-191 miR-196a2 miR-203 miR-424 miR-425 miR-760 miR-942 miR-944 (42,60-62,78, 79,86,87)
ERβ-mediated downregulation	miR-9 miR-9-3 miR-17 miR-18a miR-18b miR-19a miR-19b miR-20a miR-20b miR-21 miR-24 miR-25 miR-27b miR-30a miR-30b miR-31	miR-92a miR-106a miR-135a miR-135b miR-140-5p miR-142-3p miR-155 miR-183 miR-192 miR-194 miR-196a miR-200a miR-200b miR-221 miR-301a miR-590-5p (64,65, 88,89)
ERβ-mediated upregulation	miR-10a miR-10b miR-23b miR-24-1	miR-27b miR-191 miR-205 (64,65,87)
ERα and/or ERβ-mediated downregulation	let-7e miR-23b miR-27b miR-30c miR-125b miR-126	miR-146a miR-181a miR-200c miR-204 miR-208 miR-429 (60,63, 90-92)
ERα and/or ERβ-mediated upregulation	let-7a let-7b let-7c let-7d	miR-98 miR-106a miR-128a miR-130b (60,90,91, 93-98)

ER α and/or ER β -mediated upregulation	let-7e	miR-148a	(60,90,91, 93-98)
	let-7f	miR-155	
	let-7g	miR-182	
	let-7i	miR-200b	
	miR-7	miR-205	
	miR-17	miR-223	
	miR-18a	miR-320	
	miR-21	miR-451	
	miR-27a	miR-486	
	miR-92a-1	miR-708	
GPER1-mediated downregulation	miR-338-3p	(66)	

Only miRNAs that were validated and thoroughly studied in individual references are included in the list.

ER – estrogen receptor; miRNA – microRNA; GPER1 – G protein-coupled estrogen receptor 1.

differences in the signaling coregulators present (14,67-72). In line with this, studies observed that estrogen signaling either increased DNA methylation and subsequently epigenetically silenced target genes or predominantly demethylated DNA resulting in epigenetic upregulation of downstream targets (31,67,68,73). Furthermore, developmental exposure to relevant doses of 17 β -estradiol or xenoestrogens induced hypomethylation of certain and hypermethylation of other genes, increasing the susceptibility to certain types of adult-onset cancer (72,74,75).

Estrogen signaling end epigenetic regulation are two ubiquitous regulatory mechanisms essential for maintaining cell and tissue homeostasis. Due to their importance it is not surprising that their functions tightly intertwine. In addition, their complementary roles increase the level of cell-specificity and fine-tuning of transcriptional regulation.

Conclusions

In the last two decades, we saw a dramatic increase in our understanding of estrogen signaling.

Extragenadal synthesis of estrogens and their tight connection with androgens have extended the mechanism of estrogen action from endocrine to paracrine, autocrine and even intracrine signaling. Estrogens and androgens have lost their gender-limited roles importantly contributing to the physiology of several tissues and organ systems. Furthermore, at least three different estrogen receptors, namely ER α , ER β and GPER1, with distinct, non-redundant and in certain cases opposite roles are now known. Indirect genomic signaling through the interactions with other transcription factors at their DNA response elements and the fast non-genomic signaling mediated by membrane-bound ERs additionally increase the complexity of estrogen signaling. Importantly, estrogen signaling is also tightly connected to epigenetic mechanisms both as the regulator of gene expression of certain chromatin-modifying enzymes and miRNAs, as well as their target through the epigenetic regulation of ER gene expression levels. Moreover, certain epigenetic changes are intrinsic to estrogen-mediated transcriptional regulation and are executed at least in part by coregulators of estrogen signaling. Epigenetic mechanisms thus augment not only the intricacy but also the specificity and fine-tuning of estrogen-mediated transcriptional control. Better comprehension of the complexity of estrogen regulation has deepened our understanding of the effects of the existing estrogen receptor modulators as well as opened opportunities for the discovery of new tissue- and perhaps even cell-specific compounds.

Acknowledgments

This work was supported by the Slovenian Research Agency (grants ARMR19, P3-0298, J3-2330 and J3-5511).

Potential conflict of interest

None declared.

References

1. Hall JE. *Guyton and Hall textbook of medical physiology*. 12th ed. Philadelphia, PA: Saunders/Elsevier, 2011.
2. Nilsson S, Gustafsson J. Estrogen receptors: therapies targeted to receptor subtypes. *Clin Pharmacol Ther* 2011;89:44-55. <http://dx.doi.org/10.1038/clpt.2010.226>.
3. Labrie F. Extragonadal synthesis of sex steroids: intracrinology. *Ann Endocrinol (Paris)* 2003;64:95-107.
4. Venken K, Boonen S, Bouillon R, Vanderschueren D. Chapter 24. Gonadal Steroids. In: Rosen CJ, ed. *Primer on the metabolic bone diseases and disorders of mineral metabolism*. 7th ed. Washington: ASBMR; 2009. p. 117-23.
5. Gallou-Kabani C, Vige A, Gross MS, Junien C. Nutri-epigenomics: lifelong remodelling of our epigenomes by nutritional and metabolic factors and beyond. *Clin Chem Lab Med* 2007;45:321-7. <http://dx.doi.org/10.1515/CCLM.2007.081>.
6. Kuhlmann JD, Rasch J, Wimberger P, Kasimir-Bauer S. microRNA and the pathogenesis of ovarian cancer - a new horizon for molecular diagnostics and treatment? *Clin Chem Lab Med* 2012;50:601-15.
7. Simpson ER. Sources of estrogen and their importance. *J Steroid Biochem Mol Biol* 2003;86:225-30. [http://dx.doi.org/10.1016/S0960-0760\(03\)00360-1](http://dx.doi.org/10.1016/S0960-0760(03)00360-1).
8. Szymczak J, Milewicz A, Thijssen JH, Blankenstein MA, Daroszewski J. Concentration of sex steroids in adipose tissue after menopause. *Steroids* 1998;63:319-21. [http://dx.doi.org/10.1016/S0039-128X\(98\)00019-1](http://dx.doi.org/10.1016/S0039-128X(98)00019-1).
9. Blankenstein MA, van de Ven J, Maitimu-Smeele I, Donker GH, de Jong PC, Daroszewski J, et al. Intratumoral levels of estrogens in breast cancer. *J Steroid Biochem Mol Biol* 1999;69:293-7. [http://dx.doi.org/10.1016/S0960-0760\(99\)00048-5](http://dx.doi.org/10.1016/S0960-0760(99)00048-5).
10. Mady EA, Ramadan EE, Ossman AA. Sex steroid hormones in serum and tissue of benign and malignant breast tumor patients. *Dis Markers* 2000;16:151-7. <http://dx.doi.org/10.1155/2000/305940>.
11. Labrie F. Intracrinology. *Mol Cell Endocrinol* 1991;78:C113-8. [http://dx.doi.org/10.1016/0303-7207\(91\)90116-A](http://dx.doi.org/10.1016/0303-7207(91)90116-A).
12. Nilsson S, Mäkelä S, Treuter E, Tujague M, Thomsen J, Andersson G, et al. Mechanisms of estrogen action. *Physiol Rev* 2001;81:1535-65.
13. Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, et al. Estrogen receptors: how do they signal and what are their targets. *Physiol Rev* 2007;87:905-31. <http://dx.doi.org/10.1152/physrev.00026.2006>.
14. Ajj H, Chesnel A, Pinel S, Plenat F, Flament S, Dumond H. An alkylphenol mix promotes seminoma derived cell proliferation through an ERalpha36-mediated mechanism. *PLoS One* 2013;8:e61758. <http://dx.doi.org/10.1371/journal.pone.0061758>.
15. Filardo EJ, Thomas P. Minireview: G protein-coupled estrogen receptor-1, GPER-1: its mechanism of action and role in female reproductive cancer, renal and vascular physiology. *Endocrinology* 2012;153:2953-62. <http://dx.doi.org/10.1210/en.2012-1061>.
16. Filardo E, Quinn J, Pang Y, Graeber C, Shaw S, Dong J, et al. Activation of the novel estrogen receptor G protein-coupled receptor 30 (GPR30) at the plasma membrane. *Endocrinology* 2007;148:3236-45. <http://dx.doi.org/10.1210/en.2006-1605>.
17. Sandén C, Broselid S, Cornmark L, Andersson K, Daszkiewicz-Nilsson J, Mårtensson UE, et al. G protein-coupled estrogen receptor 1/G protein-coupled receptor 30 localizes in the plasma membrane and traffics intracellularly on cytokeleton intermediate filaments. *Mol Pharmacol* 2011;79:400-10. <http://dx.doi.org/10.1124/mol.110.069500>.
18. Lodish H, Berk A, Kaiser CA, Krieger M, Scott MP, Bretscher A, et al. *Molecular cell biology*. 6th ed. New York: W.H. Freeman and Company; 2008.
19. Björnström L, Sjöberg M. Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. *Mol Endocrinol* 2005;19:833-42. <http://dx.doi.org/10.1210/me.2004-0486>.
20. Gibney ER, Nolan CM. Epigenetics and gene expression. *Heredity (Edinb)* 2010;105:4-13. <http://dx.doi.org/10.1038/hdy.2010.54>.
21. Portela A, Esteller M. Epigenetic modifications and human disease. *Nat Biotechnol* 2010;28:1057-68. <http://dx.doi.org/10.1038/nbt.1685>.
22. Klinge CM. miRNAs and estrogen action. *Trends Endocrinol Metab* 2012;23:223-33. <http://dx.doi.org/10.1016/j.tem.2012.03.002>.
23. Mann M, Cortez V, Vadlamudi RK. Epigenetics of Estrogen Receptor Signaling: Role in Hormonal Cancer Progression and Therapy. *Cancers (Basel)* 2011;3:1691-707. <http://dx.doi.org/10.3390/cancers3021691>.
24. Bulynko YA, O'Malley BW. Nuclear receptor coactivators: structural and functional biochemistry. *Biochemistry* 2011;50:313-28. <http://dx.doi.org/10.1021/bi101762x>.
25. Kawai H, Li H, Avraham S, Jiang S, Avraham HK. Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor alpha. *Int J Cancer* 2003;107:353-8. <http://dx.doi.org/10.1002/ijc.11403>.
26. Macaluso M, Cinti C, Russo G, Russo A, Giordano A. pRb2/p130-E2F4/5-HDAC1-SUV39H1-p300 and pRb2/p130-E2F4/5-HDAC1-SUV39H1-DNMT1 multimolecular complexes mediate the transcription of estrogen receptor-alpha in breast cancer. *Oncogene* 2003;22:3511-7. <http://dx.doi.org/10.1038/sj.onc.1206578>.
27. Woodfield GW, Hitchler MJ, Chen Y, Domann FE, Weigel RJ. Interaction of TFAP2C with the estrogen receptor-alpha promoter is controlled by chromatin structure. *Clin Cancer Res* 2009;15:3672-9. <http://dx.doi.org/10.1158/1078-0432.CCR-08-2343>.
28. Hostetter CL, Licata LA, Keen JC. Timing is everything: order of administration of 5-aza 2' deoxycytidine, trichostatin A and tamoxifen changes estrogen receptor mRNA expression and cell sensitivity. *Cancer Lett* 2009;275:178-84. <http://dx.doi.org/10.1016/j.canlet.2008.10.005>.
29. Elangovan S, Ramachandran S, Venkatesan N, Ananth S, Gnana-Prakasam JP, Martin PM, et al. SIRT1 is essential for oncogenic signaling by estrogen/estrogen receptor a in breast cancer. *Cancer Res* 2011;71:6654-64. <http://dx.doi.org/10.1158/0008-5472.CAN-11-1446>.
30. Yao Y, Li H, Gu Y, Davidson NE, Zhou Q. Inhibition of SIRT1 deacetylase suppresses estrogen receptor signaling. *Carcinogenesis* 2010;31:382-7. <http://dx.doi.org/10.1093/carcin/bgp308>.

31. Leu YW, Yan PS, Fan M, Jin VX, Liu JC, Curran EM, et al. Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer. *Cancer Res* 2004;64:8184-92. <http://dx.doi.org/10.1158/0008-5472.CAN-04-2045>.
32. Walton TJ, Li G, Seth R, McArdle SE, Bishop MC, Rees RC. DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines. *Prostate* 2008;68:210-22. <http://dx.doi.org/10.1002/pros.20673>.
33. Yap OW, Bhat G, Liu L, Tollefsbol TO. Epigenetic modifications of the Estrogen receptor beta gene in epithelial ovarian cancer cells. *Anticancer Res* 2009;29:139-44.
34. Tu Z, Li H, Ma Y, Tang B, Tian J, Akers W, et al. The enhanced antiproliferative response to combined treatment of trichostatin A with raloxifene in MCF-7 breast cancer cells and its relevance to estrogen receptor β expression. *Mol Cell Biochem* 2012;366:111-22. <http://dx.doi.org/10.1007/s11010-012-1288-9>.
35. Pitta CA, Papageorgis P, Charalambous C, Constantinou AI. Reversal of ER- β silencing by chromatin modifying agents overrides acquired tamoxifen resistance. *Cancer Lett* 2013;337:167-76. <http://dx.doi.org/10.1016/j.canlet.2013.05.031>.
36. Stolzenberg DS, Stevens JS, Rissman EF. Experience-facilitated improvements in pup retrieval; evidence for an epigenetic effect. *Horm Behav* 2012;62:128-35. <http://dx.doi.org/10.1016/j.yhbeh.2012.05.012>.
37. Adams BD, Furneaux H, White BA. The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines. *Mol Endocrinol* 2007;21:1132-47. <http://dx.doi.org/10.1210/me.2007-0022>.
38. Zhao JJ, Lin J, Yang H, Kong W, He L, Ma X, et al. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. *J Biol Chem* 2008;283:31079-86. <http://dx.doi.org/10.1074/jbc.M806041200>.
39. Liu WH, Yeh SH, Lu CC, Yu SL, Chen HY, Lin CY, et al. MicroRNA-18a prevents estrogen receptor-alpha expression, promoting proliferation of hepatocellular carcinoma cells. *Gastroenterology* 2009;136:683-93. <http://dx.doi.org/10.1053/j.gastro.2008.10.029>.
40. Leivonen SK, Mäkelä R, Ostling P, Kohonen P, Haapa-Paananen S, Kleivi K, et al. Protein lysate microarray analysis to identify microRNAs regulating estrogen receptor signaling in breast cancer cell lines. *Oncogene* 2009;28:3926-36. <http://dx.doi.org/10.1038/onc.2009.241>.
41. Pandey DP, Picard D. miR-22 inhibits estrogen signaling by directly targeting the estrogen receptor alpha mRNA. *Mol Cell Biol* 2009;29:3783-90. <http://dx.doi.org/10.1128/MCB.01875-08>.
42. Castellano L, Giamas G, Jacob J, Coombes RC, Lucchesi W, Thiruchelvam P, et al. The estrogen receptor-alpha-induced microRNA signature regulates itself and its transcriptional response. *Proc Natl Acad Sci U S A* 2009;106:15732-7. <http://dx.doi.org/10.1073/pnas.0906947106>.
43. Loven J, Zinin N, Wahlstrom T, Muller I, Brodin P, Fredlund E, et al. MYCN-regulated microRNAs repress estrogen receptor-alpha (ESR1) expression and neuronal differentiation in human neuroblastoma. *Proc Natl Acad Sci U S A* 2010;107:1553-8. <http://dx.doi.org/10.1073/pnas.0913517107>.
44. Zhao Y, Deng C, Wang J, Xiao J, Gatalica Z, Recker RR, et al. Let-7 family miRNAs regulate estrogen receptor alpha signaling in estrogen receptor positive breast cancer. *Breast Cancer Res Treat* 2011;127:69-80. <http://dx.doi.org/10.1007/s10549-010-0972-2>.
45. Tang L, Pu Y, Wong DK, Liu T, Tang H, Xiang T, et al. The hepatitis B virus-associated estrogen receptor alpha (ERalpha) was regulated by microRNA-130a in HepG2.2.15 human hepatocellular carcinoma cells. *Acta Biochim Biophys Sin (Shanghai)* 2011;43:640-6. <http://dx.doi.org/10.1093/abbs/gmr051>.
46. Al-Nakhle H, Burns PA, Cummings M, Hanby AM, Hughes TA, Satheesha S, et al. Estrogen receptor {beta}1 expression is regulated by miR-92 in breast cancer. *Cancer Res* 2010;70:4778-84. <http://dx.doi.org/10.1158/0008-5472.CAN-09-4104>.
47. Issa JP, Zehnbauser BA, Civin CI, Collector MI, Sharkis SJ, Davidson NE, et al. The estrogen receptor CpG island is methylated in most hematopoietic neoplasms. *Cancer Res* 1996;56:973-77.
48. Sasaki M, Kotcherquina L, Dharia A, Fujimoto S, Dahiya R. Cytosine-phosphoguanine methylation of estrogen receptors in endometrial cancer. *Cancer Res* 2001;61:3262-6.
49. Sasaki M, Tanaka Y, Perinchery G, Dharia A, Kotcherquina L, Fujimoto S, et al. Methylation and inactivation of estrogen, progesterone, and androgen receptors in prostate cancer. *J Natl Cancer Inst* 2002;94:384-90. <http://dx.doi.org/10.1093/jnci/94.5.384>.
50. Zhao C, Lam EW, Sunter A, Enmark E, De Bella MT, Coombes RC, et al. Expression of estrogen receptor beta isoforms in normal breast epithelial cells and breast cancer: regulation by methylation. *Oncogene* 2003;22:7600-6. <http://dx.doi.org/10.1038/sj.onc.1207100>.
51. Zhu X, Leav I, Leung YK, Wu M, Liu Q, Gao Y, et al. Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis. *Am J Pathol* 2004;164:2003-12. [http://dx.doi.org/10.1016/S0002-9440\(10\)63760-1](http://dx.doi.org/10.1016/S0002-9440(10)63760-1).
52. Suzuki F, Akahira J, Miura I, Suzuki T, Ito K, Hayashi S, et al. Loss of estrogen receptor beta isoform expression and its correlation with aberrant DNA methylation of the 5'-untranslated region in human epithelial ovarian carcinoma. *Cancer Sci* 2008;99:2365-72. <http://dx.doi.org/10.1111/j.1349-7006.2008.00988.x>.
53. Wei J, Han B, Mao XY, Wei MJ, Yao F, Jin F. Promoter methylation status and expression of estrogen receptor alpha in familial breast cancer patients. *Tumour Biol* 2012;33:413-20. <http://dx.doi.org/10.1007/s13277-011-0234-x>.
54. Cohen A, Shmoish M, Levi L, Cheruti U, Levavi-Sivan B, Lubzens E. Alterations in micro-ribonucleic acid expression profiles reveal a novel pathway for estrogen regulation. *Endocrinology* 2008;149:1687-96. <http://dx.doi.org/10.1210/en.2007-0969>.

55. Elbaz A, Rivas D, Duque G. Effect of estrogens on bone marrow adipogenesis and Sirt1 in aging C57BL/6J mice. *Biogerontology* 2009;10:747-55. <http://dx.doi.org/10.1007/s10522-009-9221-7>.
56. Saji S, Kawakami M, Hayashi S, Yoshida N, Hirose M, Horiguchi S, et al. Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer. *Oncogene* 2005;24:4531-9. <http://dx.doi.org/10.1038/sj.onc.1208646>.
57. Denger S, Bähr-Ivacevic T, Brand H, Reid G, Blake J, Seifert M, et al. Transcriptome profiling of estrogen-regulated genes in human primary osteoblasts reveals an osteoblast-specific regulation of the insulin-like growth factor binding protein 4 gene. *Mol Endocrinol* 2008;22:361-79. <http://dx.doi.org/10.1210/me.2007-0292>.
58. Wickramasinghe NS, Manavalan TT, Dougherty SM, Riggs KA, Li Y, Klinge CM. Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells. *Nucleic Acids Res* 2009;37:2584-95. <http://dx.doi.org/10.1093/nar/gkp117>.
59. Zhang Y, Eades G, Yao Y, Li Q, Zhou Q. Estrogen receptor signaling regulates breast tumor-initiating cells by down-regulating miR-140 which targets the transcription factor SOX2. *J Biol Chem* 2012;287:41514-22. <http://dx.doi.org/10.1074/jbc.M112.404871>.
60. Zhao J, Imbrie GA, Baur WE, Iyer LK, Aronovitz MJ, Kershaw TB, et al. Estrogen receptor-mediated regulation of microRNA inhibits proliferation of vascular smooth muscle cells. *Arterioscler Thromb Vasc Biol* 2013;33:257-65. <http://dx.doi.org/10.1161/ATVBAHA.112.300200>.
61. Chu HW, Cheng CW, Chou WC, Hu LY, Wang HW, Hsiung CN, et al. A novel estrogen receptor-microRNA 190a-PAR-1-pathway regulates breast cancer progression, a finding initially suggested by genome-wide analysis of loci associated with lymph-node metastasis. *Hum Mol Genet* 2014;23:355-67. <http://dx.doi.org/10.1093/hmg/ddt426>.
62. Di Leva G, Piovano C, Gasparini P, Ngankeu A, Taccioli C, Briskin D, et al. Estrogen mediated-activation of miR-191/425 cluster modulates tumorigenicity of breast cancer cells depending on estrogen receptor status. *PLoS Genet* 2013;9:e1003311. <http://dx.doi.org/10.1371/journal.pgen.1003311>.
63. Maillot G, Lacroix-Triki M, Pierredon S, Gratadou L, Schmidt S, Bénès V, et al. Widespread estrogen-dependent repression of micrnas involved in breast tumor cell growth. *Cancer Res* 2009;69:8332-40. <http://dx.doi.org/10.1158/0008-5472.CAN-09-2206>.
64. Paris O, Ferraro L, Grober OM, Ravo M, De Filippo MR, Giurato G, et al. Direct regulation of microRNA biogenesis and expression by estrogen receptor beta in hormone-responsive breast cancer. *Oncogene* 2012;31:4196-206. <http://dx.doi.org/10.1038/ncr.2011.583>.
65. Edvardsson K, Nguyen-Vu T, Kalasekar SM, Pontén F, Gustafsson J, Williams C. Estrogen receptor β expression induces changes in the microRNA pool in human colon cancer cells. *Carcinogenesis* 2013;34:1431-41. <http://dx.doi.org/10.1093/carcin/bgt067>.
66. Jacovetti C, Abderrahmani A, Parnaud G, Jonas JC, Peyot ML, Cornu M, et al. MicroRNAs contribute to compensatory β cell expansion during pregnancy and obesity. *J Clin Invest* 2012;122:3541-51. <http://dx.doi.org/10.1172/JCI64151>.
67. Zhai R, Wang G, Cai K, Tao K, Xu F, Zhang W, et al. Epigenetic regulation of the ERbeta gene on the estrogen signal transfection pathway in colon cancer cells. *J Huazhong Univ Sci Technolog Med Sci* 2010;30:69-74. <http://dx.doi.org/10.1007/s11596-010-0112-6>.
68. Kubarek Ł, Jagodzinski PP. Epigenetic up-regulation of CXCR4 and CXCL12 expression by 17 beta-estradiol and tamoxifen is associated with formation of DNA methyltransferase 3B4 splice variant in Ishikawa endometrial adenocarcinoma cells. *FEBS Lett* 2007;581:1441-8. <http://dx.doi.org/10.1016/j.febslet.2007.02.070>.
69. Cui M, Wen Z, Yang Z, Chen J, Wang F. Estrogen regulates DNA methyltransferase 3B expression in Ishikawa endometrial adenocarcinoma cells. *Mol Biol Rep* 2009;36:2201-7. <http://dx.doi.org/10.1007/s11033-008-9435-9>.
70. Yamagata Y, Asada H, Tamura I, Lee L, Maekawa R, Taniuchi K, et al. DNA methyltransferase expression in the human endometrium: down-regulation by progesterone and estrogen. *Hum Reprod* 2009;24:1126-32. <http://dx.doi.org/10.1093/humrep/dep015>.
71. Logan PC, Ponnampalam AP, Steiner M, Mitchell MD. Effect of cyclic AMP and estrogen/progesterone on the transcription of DNA methyltransferases during the decidualization of human endometrial stromal cells. *Mol Hum Reprod* 2013;19:302-12. <http://dx.doi.org/10.1093/molehr/gas062>.
72. Chao HH, Zhang XF, Chen B, Pan B, Zhang LJ, Li L, et al. Bisphenol A exposure modifies methylation of imprinted genes in mouse oocytes via the estrogen receptor signaling pathway. *Histochem Cell Biol* 2012;137:249-59. <http://dx.doi.org/10.1007/s00418-011-0894-z>.
73. Marques M, Laflamme L, Gaudreau L. Estrogen receptor α can selectively repress dioxin receptor-mediated gene expression by targeting DNA methylation. *Nucleic Acids Res* 2013;41:8094-106. <http://dx.doi.org/10.1093/nar/gkt595>.
74. Cheng AS, Culhane AC, Chan MW, Venkataramu CR, Ehrlich M, Nasir A, et al. Epithelial progeny of estrogen-exposed breast progenitor cells display a cancer-like methylome. *Cancer Res* 2008;68:1786-96. <http://dx.doi.org/10.1158/0008-5472.CAN-07-5547>.
75. Ho SM, Tang WY, Belmonte de Frausto J, Prins GS. Developmental exposure to estradiol and bisphenol A increases susceptibility to prostate carcinogenesis and epigenetically regulates phosphodiesterase type 4 variant 4. *Cancer Res* 2006;66:5624-32. <http://dx.doi.org/10.1158/0008-5472.CAN-06-0516>.
76. Thomas L, ed. *Clinical laboratory diagnostics: Use and assessment of clinical laboratory results*. 1st ed. Frankfurt: TH-Books Verlagsgesellschaft mbH.; 1998.
77. Olde B, Leeb-Lundberg LM. GPR30/GPER1: searching for a role in estrogen physiology. *Trends Endocrinol Metab* 2009;20:409-16. <http://dx.doi.org/10.1016/j.tem.2009.04.006>.

78. Cicatiello L, Mutarelli M, Grober OM, Paris O, Ferraro L, Ravo M, et al. Estrogen receptor alpha controls a gene network in luminal-like breast cancer cells comprising multiple transcription factors and microRNAs. *Am J Pathol* 2010;176:2113-30. <http://dx.doi.org/10.2353/ajpath.2010.090837>.
79. Ferraro L, Ravo M, Nassa G, Tarallo R, De Filippo MR, Giurato G, et al. Effects of oestrogen on microRNA expression in hormone-responsive breast cancer cells. *Horm Cancer* 2012;3:65-78. <http://dx.doi.org/10.1007/s12672-012-0102-1>.
80. Pinho FG, Frampton AE, Nunes J, Krell J, Alshaker H, Jacob J, et al. Downregulation of microRNA-515-5p by the estrogen receptor modulates sphingosine kinase 1 and breast cancer cell proliferation. *Cancer Res* 2013;73:5936-48. <http://dx.doi.org/10.1158/0008-5472.CAN-13-0158>.
81. Lee YM, Lee JY, Ho CC, Hong QS, Yu SL, Tzeng CR, et al. miRNA-34b as a tumor suppressor in estrogen-dependent growth of breast cancer cells. *Breast Cancer Res* 2011;13:R116. <http://dx.doi.org/10.1186/bcr3059>.
82. Yu X, Zhang X, Dhakal IB, Beggs M, Kadlubar S, Luo D. Induction of cell proliferation and survival genes by estradiol-repressed microRNAs in breast cancer cells. *BMC Cancer* 2012;12:29. <http://dx.doi.org/10.1186/1471-2407-12-29>.
83. Yamagata K, Fujiyama S, Ito S, Ueda T, Murata T, Naitou M, et al. Maturation of microRNA is hormonally regulated by a nuclear receptor. *Mol Cell* 2009;36:340-7. <http://dx.doi.org/10.1016/j.molcel.2009.08.017>.
84. Di Leva G, Gasparini P, Piovan C, Ngankea A, Garofalo M, Taccioli C, et al. MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer. *J Natl Cancer Inst* 2010;102:706-21. <http://dx.doi.org/10.1093/jnci/djq102>.
85. Qian P, Zuo Z, Wu Z, Meng X, Li G, Zhang W, et al. Pivotal role of reduced let-7g expression in breast cancer invasion and metastasis. *Cancer Res* 2011;71:6463-74. <http://dx.doi.org/10.1158/0008-5472.CAN-11-1322>.
86. Kim K, Madak-Erdogan Z, Ventrella R, Katzenellenbogen BS. A MicroRNA196a2* and TP63 circuit regulated by estrogen receptor-alpha and ERK2 that controls breast cancer proliferation and invasiveness properties. *Horm Cancer* 2013;4:78-91. <http://dx.doi.org/10.1007/s12672-012-0129-3>.
87. Nagpal N, Ahmad HM, Molparia B, Kulshreshtha R. MicroRNA-191, an estrogen-responsive microRNA, functions as an oncogenic regulator in human breast cancer. *Carcinogenesis* 2013;34:1889-99. <http://dx.doi.org/10.1093/carcin/bgt107>.
88. He YQ, Sheng JQ, Ling XL, Fu L, Jin P, Yen L, et al. Estradiol regulates miR-135b and mismatch repair gene expressions via estrogen receptor-beta in colorectal cells. *Exp Mol Med* 2012;44:723-32. <http://dx.doi.org/10.3858/emmm.2012.44.12.079>.
89. Queiros AM, Eschen C, Fliegner D, Kararigas G, Dworatzek E, Westphal C, et al. Sex- and estrogen-dependent regulation of a miRNA network in the healthy and hypertrophied heart. *Int J Cardiol* 2013;169:331-8. <http://dx.doi.org/10.1016/j.ijcard.2013.09.002>.
90. Nothnick WB, Healy C. Estrogen induces distinct patterns of microRNA expression within the mouse uterus. *Reprod Sci* 2010;17:987-94. <http://dx.doi.org/10.1177/1933719110377472>.
91. Dai R, Phillips RA, Zhang Y, Khan D, Crasta O, Ahmed SA. Suppression of LPS-induced Interferon-gamma and nitric oxide in splenic lymphocytes by select estrogen-regulated microRNAs: a novel mechanism of immune modulation. *Blood* 2008;112:4591-7. <http://dx.doi.org/10.1182/blood-2008-04-152488>.
92. Kong X, Xu X, Yan Y, Guo F, Li J, Hu Y, et al. Estrogen regulates the tumour suppressor miRNA-30c and its target gene, MTA-1, in endometrial cancer. *PLoS One* 2014;9:e90810. <http://dx.doi.org/10.1371/journal.pone.0090810>.
93. Bhat-Nakshatri P, Wang G, Collins NR, Thomson MJ, Geistlinger TR, Carroll JS, et al. Estradiol-regulated microRNAs control estradiol response in breast cancer cells. *Nucleic Acids Res* 2009;37:4850-61. <http://dx.doi.org/10.1093/nar/gkp500>.
94. Masuda M, Miki Y, Hata S, Takagi K, Sakurai M, Ono K, et al. An induction of microRNA, miR-7 through estrogen treatment in breast carcinoma. *J Transl Med* 2012;10:S2. <http://dx.doi.org/10.1186/1479-5876-10-S1-S2>.
95. Zhang C, Zhao J, Deng H. 17beta-estradiol up-regulates miR-155 expression and reduces TP53INP1 expression in MCF-7 breast cancer cells. *Mol Cell Biochem* 2013;379:201-11. <http://dx.doi.org/10.1007/s11010-013-1642-6>.
96. Wang G, Wang Y, Shen C, Huang YW, Huang K, Huang TH, et al. RNA polymerase II binding patterns reveal genomic regions involved in microRNA gene regulation. *PLoS One* 2010;5:e13798. <http://dx.doi.org/10.1371/journal.pone.0013798>.
97. Zhang R, He Y, Zhang X, Xing B, Sheng Y, Lu H, et al. Estrogen receptor-regulated microRNAs contribute to the BCL2/BAX imbalance in endometrial adenocarcinoma and precancerous lesions. *Cancer Lett* 2012;314:155-65. <http://dx.doi.org/10.1016/j.canlet.2011.09.027>.
98. Cochrane DR, Cittelly DM, Howe EN, Spoelstra NS, McKinsey EL, LaPara K, et al. MicroRNAs link estrogen receptor alpha status and Dicer levels in breast cancer. *Horm Cancer* 2010;1:306-19. <http://dx.doi.org/10.1007/s12672-010-0043-5>.